Biotechs applaud tax cut move to keep Aussie research
The federal government’s ‘patent box’ will almost halve the tax rate on Australian research that is commercialised locally.
Csl
ASX roars back; Newcrest sinks 6.4%
Local shares rose 2.2% to close out a volatile week, bond yields cooled slightly and the Aussie dollar hit a seven-week low.
CSL’s Vifor deal to boost earnings
Analysts believe CSL will have an earnings up lift of more than 2 per cent next financial year after buying Vifor Pharma for $16.4bn.
ASX tanks as investors bail
ASX has entered a technical ‘correction’ as investors dump stocks including CSL, CBA and Woodside. Evolution Mining and Silver Lake Resources were also battered, dropping more than 10 per cent.
CSL ends Covid-19 research battle
CSL is turning to other projects in its $1bn-a-year research program, ending its aim to develop antiviral Covid-19 treatments.
ASX stocks down led by tech, health losses
The ASX 200 index is trading lower with gains among the big miners and banks being offset by weaker tech and health players.
Floating feeling: bumper year for equity capital markets
The Australian equity capital markets experienced their busiest period ever during 2021, with over 1000 issues, beating 2020, according to data from Refinitiv.
Top 10 firms reveal their biggest issues
CBA, CSL, BHP, Westpac, NAB, ANZ, Fortescue, Wesfarmers, Macquarie, Telstra.
Strong jobs numbers ‘toxic’ for ASX
The RBA can keep insisting rate hikes won’t come in 2022, but the ASX isn’t buying it, with strong jobs numbers fuelling bets it will do just that.
CSL placement priced at $273/share
A decision on the price for CSL’s $6.3bn placement was said to have gone down to the wire.
ASX falls, IGO climbs on deal, CSL dives 8.2%
ASX closes 0.43 per cent lower, pulled down by CSL sell off; EML Payments faces class action, IGO gains after Western Areas buy and jobless rate falls to 4.6 per cent.
M&A mega deal on track for Christmas
CSL’s $16.4bn transformational acquisition may have shocked the market by landing so close to the end of the year, but apparently there’s one more mega deal looming before Christmas.
CSL’s $16.4bn offer for Vifor wins cautious backing
Investment banks have warily backed CSL’s $16.4bn takeover bid for Vifor Pharma, but some wonder if the acquisition will be a good fit.
CSL taps HSBC to fund mega deal
Australia’s largest biotechnology company is funding its $16.4bn Vifor Pharma acquisition with $US6bn of debt.
Woolworths profit warning a stark worry
All businesses big and small should be alarmed about Woolworths’ profit warning which is set to send chills through boardrooms.
CSL offers $16.4bn for Vifor Pharma in friendly deal
CSL has lobbed a $16.4bn takeover offer for European firm Vifor Pharma in a transaction that will transform it into a global pharmaceutical giant.
CSL to argue case for Vifor Pharma acquisition
Hot on the heels of announcing its mammoth $16.4bn acquisition of Vifor Pharma, CSL will now be focused on selling the deal to investors.
CSL to buy Vifor for $16.4bn
The healthcare group has announced a hefty capital raising to fund its acquisition of the Swiss Vifor Pharma.
How CSL sparked a global pharma transformation
Australia’s largest biotech group is set to transform into a global pharma giant following its pending deal with Vifor Pharma and amid the mRNA saga.
CSL planning Vifor analyst briefing after ASX close
Analysts have been told to prepare for an aftermarket briefing on an acquisition by CSL of Vifor Pharma.
Original URL: https://www.theaustralian.com.au/topics/csl/page/7